BPC-157 Shows Consistent Fistula Healing in Rat Studies Across Multiple Organ Systems | Research

The takeaway

BPC-157, a stable gastric pentadecapeptide, demonstrated consistent fistula healing across multiple organ systems in rat models, acting as a novel mediator of Robert's cytoprotection.

Consistent healing across organs
BPC-157 healed fistulas in rat models across gastrointestinal and other organ systems

What the researchers found

BPC-157 consistently promoted fistula healing in rat models across multiple organ systems, with effects linked to its anti-ulcer, cytoprotective, and wound-healing properties as a native gastric peptide.

Why it matters

Fistulas are serious surgical complications often resistant to treatment. If BPC-157's consistent rat results translate to humans, it could offer a non-surgical fistula healing approach.

The numbers in context

6+ external fistula types; internal fistulas (colovesical, rectovaginal); 7 anastomosis types; no LD1 found; stable in gastric juice >24h

How the study worked

Literature review of BPC-157 studies in rat fistula models, covering gastrointestinal and other organ system fistulas, mechanism of action, and connection to cytoprotection.

Who was studied

Review of rat studies

What this study cannot tell us

All data from rat models — no human fistula healing trials. BPC-157 is not FDA-approved. Mechanisms remain partially understood. Review from researchers heavily involved in BPC-157 research.

How to read the evidence

Preliminary — consistent rat results but no human clinical data for fistula healing specifically.

When this study was published

Published in 2020; BPC-157 remains widely discussed in both research and peptide supplement communities.

The bigger picture

BPC-157's fistula healing extends its already broad wound-healing profile (tendons, muscles, gut ulcers) and supports its proposed role as a fundamental tissue repair mediator.

Questions still open

Would BPC-157 heal fistulas in humans, particularly Crohn's fistulas?
What is the optimal route and dose for fistula-specific BPC-157 therapy?
How does BPC-157 fistula healing compare to existing surgical and biologic treatments?

Common questions

What is a fistula and why is it hard to treat?

A fistula is an abnormal tunnel between two body surfaces or organs, often caused by surgery, injury, or disease like Crohn's. They often resist healing because of ongoing infection, poor blood supply, and the continuous passage of bodily fluids through the tract.

Is BPC-157 available for fistula treatment?

BPC-157 is not FDA-approved for any medical condition. While rat studies show consistent fistula healing, human clinical trials have not been conducted specifically for this application.

Read the original research

Fistulas Healing. Stable Gastric Pentadecapeptide BPC 157 Therapy.

Current pharmaceutical design, 26(25), 2991-3000

View on PubMed ↗Publisher’s paper ↗

Citation

Sikiric, Predrag; Drmic, Domagoj; Sever, Marko; Klicek, Robert; Blagaic, Alenka B; Tvrdeic, Ante; Kralj, Tamara; Kovac, Katarina K; Vukojevic, Jaksa; Siroglavic, Marko; Gojkovic, Slaven; Krezic, Ivan; Pavlov, Katarina H; Rasic, Domagoj; Mirkovic, Ivan; Kokot, Antonio; Skrtic, Anita; Seiwerth, Sven. (2020). Fistulas Healing. Stable Gastric Pentadecapeptide BPC 157 Therapy.. Current pharmaceutical design, 26(25), 2991-3000. https://doi.org/10.2174/1381612826666200424180139